Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03492099 · ClinicalTrials.gov registry record · Phase 2
Assessing the Safety of Buprenorphine in People With Sickle Cell Disease
A Phase 2 study, sponsored by Johns Hopkins University.
- Completed
- Registry status
- Phase 2
- Development phase
- 47
- Enrollment target
NCT03492099: Completed Phase 2 study, sponsored by Johns Hopkins University.
NCT03492099 is a Phase 2 study that has completed, run by Johns Hopkins University. The registered enrollment target is 47 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03492099, a Phase 2 study, has completed, sponsored by Johns Hopkins University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 47 participants
- Enrollment target
Study Summary
This study will assess the safety of changing pain medications (opioids) adult sickle cell patients take to another type of medication therapy (buprenorphine). Patients will be asked questions about their quality of life. Other tools for assessment will also be administered.
Interventions
- DRUG buprenorphine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 47 participants |
| Start Date | 2018-08-01 |
| Est. Completion | 2022-02-28 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03492099
The ClinicalTrials.gov registry entry for NCT03492099 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 47 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Johns Hopkins University, which has 1,448 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which buprenorphine is the first listed.
NCT03492099 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03492099 about?
NCT03492099 is a clinical study titled "Assessing the Safety of Buprenorphine in People With Sickle Cell Disease". This study will assess the safety of changing pain medications (opioids) adult sickle cell patients take to another type of medication therapy (buprenorphine). Patients will be asked questions about their quality of life. Other tools for assessment will also be administered.
What is the current status of trial NCT03492099?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 47 participants. The study started on 2018-08-01. Estimated completion is 2022-02-28.
What interventions are being tested in trial NCT03492099?
The interventions under investigation include: buprenorphine (DRUG).
Who is sponsoring clinical trial NCT03492099?
This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.